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1 
Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical 1 
overview 2 
Abstract:  3 
Since 1997, studies have found that Asians need lower clozapine doses than Caucasians. 4 
Caucasians with average clozapine metabolism may need from 300 to 600 mg/day to reach the 5 
therapeutic range (350 ng/ml). Thus, serum clozapine concentration-to-dose (C/D) ratios 6 
typically range between 0.60 (male smokers) and 1.20 (female non-smokers). A 2019 systematic 7 
review of clozapine levels demonstrated weighted mean C/D ratios of 1.57 in 876 East Asians 8 
and 1.07 in 1147 Caucasians (p<.001). In Asian countries, average clozapine doses are lower than 9 
300 mg/day. After sex and smoking stratification in five Asian samples with clozapine 10 
concentrations, the clozapine dose required to reach 350 ng/ml in female non-smokers ranged from 11 
145 to 189 mg/day and in male smokers, from 259 to 294 mg/day.  Thus, in Asian patients with 12 
average metabolism (with no inducers other than smoking, with no inhibitors, and in the absence of 13 
extreme obesity), the dose needed for clinical response may range between 150 mg/day for female 14 
non-smokers to 300 mg/day for male smokers. Clozapine levels may help personalize dosing in 15 
clozapine poor metabolizers (PMs) and ultrarapid metabolizers (UMs).  Asian PMs may need very 16 
low doses (50-150 mg/day) to obtain therapeutic concentrations. About 10% (range 2%-13%) of 17 
Asians are genetic PM cases. Other PMs are patients taking CYP1A2 inhibitors such as 18 
fluvoxamine, oral contraceptives, and valproate. Temporary clozapine PM status may occur during 19 
severe systemic infections/inflammations with fever and C-reactive protein (CRP) elevations.  20 
Asian UMs include patients taking potent inducers such as carbamazepine or phenytoin, and rarely, 21 
valproate.         22 
 23 
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 27 
This review article proposes that the clozapine package insert (or drug labeling) and psychiatric 28 
literature should inform physicians that Asian patients with average clozapine metabolism are 29 
likely to need between 150 and 300 mg/day of clozapine to reach therapeutic concentrations, in 30 
contrast with Caucasian patients with average clozapine metabolism, who need 300 to 600 31 
mg/day.  32 
 33 
WHAT IS THE EVIDENCE? 34 
A reader familiar with United States psychiatric textbooks[1] or review articles[2] or British 35 
textbooks[3] or guidelines[4] may find the title of this article surprising. A British textbook[3] 36 
states, “The range [for clozapine dosing] is approximately 250 mg/day (female non-smoker) to 37 
550 mg/day (male smoker)” and makes no reference to Asian patients.  38 
 39 
Average response in randomized clinical trials (RCTs) is used by pharmaceutical companies to 40 
provide recommended average doses, but this approach is misguided when statistical 41 
heterogeneity is present and when the mean does not represent the heterogeneous sample well.[5]  42 
As a matter of fact, the question asked in a Cochrane review, “What is the optimal dose for 43 
clozapine in schizophrenia?”[6], is an irrelevant  question because there is no average clozapine 44 
dose that is “best”; the right dose depends on the clozapine clearance of the individual patient, 45 
which is mainly mediated by CYP1A2 and is significantly influenced by ethnicity, smoking 46 
3 
status and sex, all of which have major influence on CYP1A2 activity.[7]  A better question, 47 
therefore, is to ask what dose is optimal for specific sub-groups: 1) Asian non-smoker females, 48 
2) Asian non-smoker males, 3) Asian smoker females, 4) Asian smoker males, 5) non-Asian 49 
non-smoker females, 6) non-Asian non-smoker males, 7) non-Asian smoker females, and 8) non-50 
Asian smoker males.[8]          51 
 52 
These questions are at the heart of clinical practice but were not asked when clozapine was 53 
introduced in the market. Traditionally, drug studies for approval focused on Caucasian subjects, 54 
predominantly male, but this state of affairs is no longer satisfactory. The current need is to 55 
understand how different racial and ethnic ancestry can lead to differences in efficacy and safety 56 
in the use of various drugs.  57 
 58 
WHO ARE ASIANS? 59 
According to the Food and Drug Administration, the Asian phenotype includes people whose 60 
ancestral origins range geographically from Pakistan to Japan.[9] Within that group is a more 61 
homogeneous genetic group called East Asians, who comprise Chinese, Korean, Japanese, and 62 
Mongolian people. This classification is largely driven by the history of genetic evolution.[10]  63 
This means that people from Western Asia[11] are genetically different from other Asians and are 64 
closer to Caucasian Europeans;[10] it also means that the original people from the Americas[10] are 65 
really descended from East Asians and are likely to be genetically close to East Asians.  In this 66 
review, we report clozapine levels from Vellore, which probably reflects a population from 67 
Southern India, while the Northern India population probably includes a more complex mix.[12]  68 
 69 
4 
THE EVIDENCE FROM CLOZAPINE BLOOD LEVELS 70 
Although clozapine prescribers in Western countries are not aware that Asians need lower 71 
clozapine doses, this is not a new concept. In 1997 Chang et al.[13] and Chong et al.[14]  showed 72 
that Chinese patients who used half the clozapine dosage had concentrations similar to 73 
Caucasians. Moreover, in 2005, Ng et al.[15] found that 20 Singaporean Asians (from three ethnic 74 
groups: Chinese, Indian, and Malay) had higher clozapine concentration-to-dose (C/D) ratios 75 
than 20 Australian Caucasians.   76 
 77 
The clozapine C/D ratio is a measure of clozapine drug clearance, which can be influenced by 78 
genetic, personal, and environmental factors.[16] The clozapine C/D ratio can be used to 79 
distinguish patients based on clozapine metabolism. Thus, patients with a very low clozapine 80 
C/D ratio belong to an ultrarapid metabolizer (UM) phenotype, while those with a very high C/D 81 
ratio belong to a poor metabolizer (PM) phenotype. In 2015, a review[16] proposed that in US 82 
schizophrenia patients, Caucasians with average clozapine metabolism usually need 300-600 83 
mg/day to reach the lowest part of the therapeutic range (350 ng/ml). US male smokers usually 84 
reach a therapeutic concentration of ≥350 ng/ml with a dosage of 600 mg/day; this corresponds 85 
to a C/D ratio of 0.58 (350/600). US female non-smokers usually reach a concentration of ≥350 86 
ng/ml with a dosage of only 300 mg/day; this corresponds to a C/D ratio of 1.17 (350/300). 87 
Therefore, in the US, clozapine C/D ratios typically range between approximately 0.60 and 88 
1.20.[16]   89 
 90 
Based on the limited published data on Chinese patients[13-15] and the fact that clozapine follows 91 
linear kinetics, the review16 also proposed that East Asians may have clozapine C/D ratios that 92 
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are twice as high, ranging from 1.20 to 2.40, which means that they need only half the clozapine 93 
dosage of US Caucasians.[16] In 2019, a systematic review of clozapine levels supported that 94 
conclusion,[8] since the clozapine C/D ratio was higher when comparing weighted mean values of 95 
1.57 in 876 East Asians and 1.07 in 1147 Caucasians (p<.001).  Interestingly, a Mexican study[17] 96 
which provided no information on patient ethnicity described clozapine C/D ratios similar to 97 
East Asians.    98 
 99 
THE EVIDENCE FROM CLOZAPINE DOSING IN ASIAN COUNTRIES 100 
In 1998, Farooq[18] reported his clinical observation that Pakistani psychiatrists also used lower 101 
doses similar to those used by Chinese psychiatrists, and proposed that Pakistanis also have 102 
lower clozapine clearance than Caucasians, but similar to Chinese.  However, these comments on 103 
the need for low clozapine doses in Chinese and Pakistani patients were largely ignored in 104 
Western countries.  105 
 106 
Clozapine is widely used in China. In 2012, Wang and Li[19] stated that the mean dose reported 107 
in Chinese studies was 216 mg/day, which was much lower than the 431 mg/day reported in the 108 
non-Chinese literature.  A dosing study with >3,000 samples from the Japanese clozapine 109 
database described a mean dose of 186 mg/day.[20]  In a survey of 117 Indian psychiatrists, 110 
Shrivastava and Shah[21] indicated that almost all (86%) of their patients were stabilized on 111 
clozapine doses lower than 300 mg/day.  A recent Asian review described clozapine daily dosing 112 
in single samples from several different countries. In countries with no published blood levels, 113 
the sample average doses (in mg/day) were 368 in Sri Lanka, 364 in Malaysia, 245 in Thailand, 114 
193 in Myanmar, 182 in Vietnam, 158 in Pakistan, 142 in Bangladesh and 58 in Indonesia.[22] 115 
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 116 
DOSING RECOMMENDATION FOR ASIANS IN THE ABSENCE OF BLOOD 117 
LEVELS 118 
If the psychiatrist has access to blood levels, the best way to personalize clozapine dosing[23] is to  119 
use a dose that provides a trough steady-state clozapine concentration of at least 350 ng/ml.[24]  120 
Alternatively, the data from the five Asian samples,[25]  after sex and smoking stratification, can 121 
be used to orient Asian clinicians who have no access to an assessment of blood levels. The five 122 
samples were from Beijing, [8,26] Taipei,[27] Seoul[28], and Vellore.[29] In these five Asian samples, 123 
the clozapine dose required to reach at least 350 ng/ml in female non-smokers ranged from 145 124 
to 189 mg/day and in male smokers, from 259 to 294 mg/day. 125 
 126 
These clozapine dosing guidelines are based on patients with average metabolism who are not 127 
using inducers (other than smoking) or inhibitors and do not have extreme obesity. The dose 128 
needed for clinical response in Asian patients with average clozapine metabolism ranges between 129 
150 mg/day for female non-smokers and 300 mg/day for male smokers. After reaching these 130 
doses, when a psychiatrist is faced with the need to ascertain whether the patient is not going to 131 
respond to clozapine, they may want to reach at least 200 mg/day in an Asian female non-smoker 132 
before declaring her to be non-responsive; likewise, an Asian male smoker will need at least 350 133 
mg/day. Asian female smokers and Asian non-smoking males will need intermediate doses.  134 
 135 
THE IMPORTANCE OF USING CLOZAPINE BLOOD LEVELS IN ASIANS 136 
7 
This review has so far focused on Asian non-smoking females or Asian smoking males with 137 
average metabolism, but not all patients are average for clozapine metabolism. Clozapine PMs 138 
and UMs exist, and they can be genetic or non-genetic PMs or UMs.  139 
 140 
In the five Asian samples,[25] approximately 10% (range 2-13%) of possible genetic clozapine 141 
PMs needed very low clozapine doses of approximately 50-125 mg/day to reach 350 ng/ml. In 142 
Vellore, the PM percentage appeared to be 2%. Moreover, phenoconversion by environmental 143 
and personal variables can make a normal clozapine metabolizer appear to be a phenotypical 144 
clozapine PM. Fluvoxamine is an extremely powerful inhibitor of clozapine metabolism that 145 
makes most patients resemble clozapine PMs,[30] and should never be co-prescribed with 146 
clozapine in the absence of access to blood levels.  Other powerful inhibitors of clozapine 147 
metabolism that are likely to make a patient a clozapine PM are: ciprofloxacin, oral 148 
contraceptives, and high doses of caffeine.  Phenothiazines, tricyclic antidepressants, and high 149 
doses of sertraline can also phenoconvert patients to clozapine PM.[30]  Valproic acid in some 150 
patients may also inhibit clozapine metabolism.[29,31]   More importantly, using the clozapine C/D 151 
ratio in the Vellore sample, we estimated that a clozapine PM male smoker who was taking 152 
valproic acid would only need 105 mg/day to get therapeutic concentrations.[25]    153 
 154 
Clozapine deposits in fat tissue,[32] and this decreases clozapine clearance. After combining four 155 
Asian samples with measures of weights, we found that 1.1% (5/429) of patients appear to be 156 
phenotypic clozapine PMs due to extreme obesity.[25] 157 
 158 
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The most common cause of clozapine phenotypic PM status may be a severe infection or severe 159 
inflammation with systemic manifestations that include fever and/or elevations of c-reactive 160 
protein (CRP). The inflammation releases cytokines that inhibit CYP1A2 and other CYPs, 161 
thereby increasing clozapine levels.[33]  Most clinicians are not aware that pneumonia can be 162 
lethal in clozapine patients because it can lead to clozapine intoxication.[34] Halving the clozapine 163 
dose when pneumonia is diagnosed, or when any serious inflammation/infection with fever 164 
and/or CRP elevation occurs, may avoid the development of clozapine intoxication.[33,34]  The 165 
complexities involved in diagnosing fever in clozapine patients are reviewed in a recent 166 
article.[35]   167 
 168 
Patients taking a potent inducer such as rifampicin or one of the three potent antiepileptic 169 
inducers, , phenytoin or phenobarbital, can become clozapine UMs and require much higher 170 
clozapine doses.[30] Valproic acid, instead of being an inhibitor of clozapine metabolism, can be 171 
an inducer in some patients. Studies suggest that when valproic acid acts as an inducer, it mainly 172 
induces norclozapine metabolism[31,36-38] but can sometimes contribute to the patient becoming a 173 
UM who needs very high clozapine doses. [39] Norclozapine is clozapine’s main metabolite and 174 
has no antipsychotic efficacy but may contribute to adverse drug reactions. [40] In summary, in 175 
some clozapine patients, valproic acid  can act as an inhibitor of clozapine metabolism and in 176 
others, as an inducer, particularly of norclozapine metabolism.[41] During early titrations, it is 177 
important to consider the risk of inhibition.  178 
 179 
Mild CYP1A2 inducers are omeprazole and intake of cruciferous vegetables such as broccoli. 180 
These latter compounds and the polycyclic aromatic hydrocarbons (PAH) found in the smoke of 181 
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tobacco  bind to the aryl hydrocarbon receptor (AhR), inducing CYP1A2 expression.[42] The 182 
same PAH in barbecued food can act as it does in tobacco smoke, but one would have to 183 
consume great quantities of barbecued food to gain the same effect as daily smoking. More 184 
importantly, in people from India or Sri Lanka,[43] high coffee intake has been associated with 185 
induction of CYP1A2 expression, possibly because of the way the coffee beans are roasted.  186 
Using the clozapine C/D ratio in the Vellore sample, we estimated that a particular clozapine UM 187 
would need 1029 mg/day of clozapine to reach a clozapine level of 350 ng/ml. She was a non-188 
smoking female who reported consuming 10 cups of coffee/day, much higher than other patients. 189 
Assuming that her single clozapine level was not contaminated by lack of adherence, she 190 
appeared to be a clozapine UM explained by the high induction produced by the roasting of 191 
coffee beans.[25] 192 
 193 
In conclusion, the best way of personalizing dosing for clozapine PMs and UMs, whether genetic 194 
or non-genetic by source, is to measure clozapine blood levels.[23]  195 
 196 
THE NEED FOR STARTING WITH LOWER DOSES AND SLOWER TITRATION IN 197 
ASIAN PATIENTS 198 
Asian patients need half the dose to which Caucasian patients are usually up-titrated. Therefore 199 
to prevent myocarditis, in Asians, it may be desirable to start with 12.5 mg/day and, if tolerated, 200 
to reach 50 mg/day at day 7, 100 mg/day at day 14, and 150 mg/day at day 21. Then, after 201 
reaching a steady-state (five days later), a trough clozapine level could be obtained to personalize 202 
dosing. It is preferable to require a normal CRP level for starting clozapine, or else systemic 203 
inflammation-related reduction in clozapine metabolism may compromise the safety of the 204 
10 
titration.[23,44] Weekly CRP can be measured with the white blood count (WBC); if the CRP is 205 
elevated, clozapine should be stopped until the CRP normalizes because this may be an initial 206 
sign of clozapine-induced inflammation that can progress to myocarditis.[23,44] Frequently, 207 
clozapine up-titration is conducted in the background of a prior antipsychotic, and so delaying 208 
clozapine titration until CRP normalizes is safe. If the patient is not already taking another 209 
antipsychotic, an additional antipsychotic can be given until it is determined that the patient can 210 
tolerate a slower clozapine up-titration.   211 
 212 
Two articles have independently proposed that clozapine-induced myocarditis is a hypersensitive 213 
reaction similar to lamotrigine-induced Stevens-Johnson syndrome that is produced by rapid up-214 
titration.[45,46] Normal titration may lead to myocarditis in clozapine PMs, such as those taking 215 
valproic acid. [47] If the clozapine up-titration is too fast for a specific patient, a clozapine-216 
induced inflammation will develop, manifested as CRP elevation; this will further reduce 217 
clozapine metabolism and predispose to myocarditis.  The high incidence of clozapine-induced 218 
myocarditis in Australia may be partly explained by the use of Caucasian-level titration in 219 
patients of Asian ancestry, considering the increase in Asian emigration to Australia in the last 220 
ten years.[8] 221 
 222 
INTERPRETING CLOZAPINE BLOOD LEVELS 223 
Clinicians frequently fail to understand that a single clozapine level must be viewed with caution 224 
and that a pattern change across several levels is easier to interpret. Laboratory, technical, and 225 
natural variations can cause some day-to-day variations in clozapine levels, even after assuming 226 
the stability of all possible confounding factors such as trough (early morning before medication 227 
11 
intake) and steady-state levels (≥5 days with no clozapine dose change), drug interactions, 228 
smoking, and caffeine intake.[48] The most important changes in clozapine levels in outpatients 229 
are due to a lack of compliance.[49] Based on an RCT in an inpatient setting with very strict 230 
control over compliance and many levels every other week for months,[50] we have suggested 231 
that only a change by a factor of 2 is probably meaningful from the clinician’s perspective. This 232 
means that if an individual has a clozapine level of 500 ng/ml, the next one under the same stable 233 
conditions should not be >1000 or <250 ng/ml. However, a change from 500 to 400 ng/ml is 234 
probably not significant.[48] 235 
 236 
CONCLUSION 237 
This review article proposes that Asians, defined as people whose ancestral origins range 238 
geographically from Pakistan to Japan, and who comprise up to 50% of the world’s population, 239 
may need half the clozapine dosage used in Western countries.  Psychiatrists in India, and more 240 
widely, in Asia, need to be aware that the clozapine doses needed by Asian patients are half 241 
those needed by Caucasian patients.  242 
 243 
Based on the evidence presented in this article, Asian psychiatrists should encourage their 244 
hospitals and facilities, where possible, to developing laboratories that can allow obtaining 245 
clozapine levels to become routine practice. This would help personalize clozapine dosing.  246 
Asian pharmaceutical companies should consider developing clozapine formulations that allow 247 
lower doses, such as 12.5, 10, or even 5 mg. These low doses are far more appropriate for 248 
starting clozapine in Asian patients.  This article estimates dosing for Asians based on linear 249 
kinetics and the estimation that the lower therapeutic range is 350 ng/ml, but this value is mainly 250 
12 
based on studies in Caucasians and response-plasma levels in Asians are needed. Future studies 251 
in Asian patients need to establish whether or not this value (350 ng/ml) needs to be modified in 252 
Asians.    253 
254 
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